How to Help Your Patients Find Imuran in Stock: A Provider's Guide

As a prescriber of azathioprine (Imuran), you've likely heard from patients who are having trouble filling their prescriptions. While the oral tablet supply situation is not a formal FDA shortage, uneven distribution means many patients encounter empty pharmacy shelves — and then turn to you for help. This guide gives you practical tools and talking points to support patients through the access process without adding significant burden to your clinical workflow.

Why Patients Are Struggling to Find Azathioprine

The injectable formulation of azathioprine is on the FDA shortage list (Hikma 100 mg vials, back ordered since late 2024). The oral formulation is not formally in shortage, but patients experience localized gaps due to:

A limited pool of generic manufacturers — disruption at any one facility tightens supply for all

Wholesaler allocation patterns that favor large chain pharmacies over independents

Injectable shortage spillover — hospitals crushing oral tablets for patients who cannot swallow, adding to retail demand

Broad cross-specialty prescription volume from rheumatology, gastroenterology, nephrology, neurology, and dermatology

Prescribing Strategies That Reduce Access Barriers

Small adjustments to how you write prescriptions can make a large difference in whether your patients can fill them:

Prescribe 90-day supplies. Most insurance plans cover 90-day fills at mail-order or preferred pharmacies. Patients who refill every 90 days search for supply three times per year instead of twelve — dramatically reducing the burden of the current availability landscape.

Write for "azathioprine 50 mg tablet" generically. Writing for any generic manufacturer (rather than a specific label) allows the pharmacist to substitute the most available manufacturer's product without a call to your office.

Recommend mail-order pharmacy enrollment. Mail-order pharmacies stock immunosuppressants more reliably than retail locations because they carry larger inventories. For stable, long-term patients on azathioprine, mail-order significantly reduces the risk of supply gaps.

Route patients to specialty pharmacies. Hospital-affiliated or transplant-specialty pharmacies tend to maintain more reliable azathioprine stock because their core patient population depends on this medication continuously.

Tools to Share With Patients at the Point of Prescribing

medfinder: A service that calls pharmacies near the patient to check which ones have their medication in stock. Patients provide their drug name, dosage, and location — medfinder contacts pharmacies and texts results back. Consider printing the URL (medfinder.com/providers) on your after-visit summary or having it available as a patient handout.

GoodRx and SingleCare: Both platforms have pharmacy locators showing which stores in a given zip code carry azathioprine and at what price. These tools also help uninsured or underinsured patients access generic azathioprine for as low as $13–$17 per month.

NeedyMeds.org and RxAssist.org: For patients facing both availability and cost barriers, these platforms connect patients with patient assistance programs, copay cards, and community resources.

What to Do When a Patient Reports They Cannot Find Their Medication

When a patient calls your office or portal reporting they cannot find azathioprine, a rapid, structured response prevents dose gaps:

Assess urgency based on indication. Transplant patients require immediate attention. RA or IBD patients in stable remission may have a slightly larger window.

Contact your in-house or partner pharmacy directly. Hospital-affiliated pharmacies or pharmacies you have a working relationship with can often special-order or transfer stock more quickly than the patient can arrange on their own.

Confirm the patient has tried GoodRx/medfinder to locate stock at nearby pharmacies before escalating to an alternative medication conversation.

If supply is unavailable for more than a few days for a high-risk patient, initiate your alternative protocol (see below).

Established Alternative Protocols by Indication

Transplant (antiproliferative): Mycophenolate mofetil (CellCept 500 mg BID) or mycophenolate sodium (Myfortic). Coordinate with transplant team.

IBD (thiopurine-dependent): Mercaptopurine (also in shortage 2026); mycophenolate mofetil off-label; biologic escalation for moderate-severe cases.

Rheumatoid arthritis: Leflunomide, hydroxychloroquine, or biologic DMARD depending on disease history.

Lupus nephritis: Mycophenolate mofetil (well-evidenced for LN maintenance); coordinate with nephrology.

For the full clinical shortage context, see our article Imuran Shortage: What Providers and Prescribers Need to Know in 2026. For a quick tool to give patients at the point of prescribing, visit medfinder for providers.